ahlam1399
10-01-2016, 10:00 PM
Morphosys moves closer to getting first antibody drug on market
FRANKFURT, Oct 1 (Reuters) - German biotech Morphosys moved a step closer to getting its first antibody drugonto the market as its licensee, Johnson & Johnson unit Jenssen, reported positive results from a phase 3 study ofpsoriasis drug guselkumab.http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=Oq1UB3yueB0:L2ofKuLqbSE:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=Oq1UB3yueB0:L2ofKuLqbSE:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=Oq1UB3yueB0:L2ofKuLqbSE:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=Oq1UB3yueB0:L2ofKuLqbSE:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=Oq1UB3yueB0:L2ofKuLqbSE:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/Oq1UB3yueB0
FRANKFURT, Oct 1 (Reuters) - German biotech Morphosys moved a step closer to getting its first antibody drugonto the market as its licensee, Johnson & Johnson unit Jenssen, reported positive results from a phase 3 study ofpsoriasis drug guselkumab.http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=Oq1UB3yueB0:L2ofKuLqbSE:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=Oq1UB3yueB0:L2ofKuLqbSE:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=Oq1UB3yueB0:L2ofKuLqbSE:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=Oq1UB3yueB0:L2ofKuLqbSE:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=Oq1UB3yueB0:L2ofKuLqbSE:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/Oq1UB3yueB0